GILEAD SCIENCES DL-,001/ US3755581036 /
| 5/27/2024 8:53:56 PM | Chg. -0.010 | Volume | Bid5/27/2024 | Ask5/27/2024 | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 60.210EUR | -0.02% | 240 Turnover: 14,553.500 |
60.210Bid Size: 600 | 60.470Ask Size: 600 | 75.47 bill.EUR | - | - |
GlobeNewswire
5/22
Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congres...
GlobeNewswire
5/14
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results
GlobeNewswire
5/9
MacroGenics Provides Update on Corporate Progress, First Quarter 2024 Financial Results and Interim ...
GlobeNewswire
5/9
HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights
GlobeNewswire
5/8
Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update
GlobeNewswire
5/8
Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights
GlobeNewswire
4/29
Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Eva...
GlobeNewswire
4/19
ACTG Announces Launch of Clinical Trial Evaluating Combination of Three Novel Immune-based Therapies...
GlobeNewswire
4/10
Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Upda...
GlobeNewswire
4/2
Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences
GlobeNewswire
4/1
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Fin...
GlobeNewswire
3/28
Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlight...
GlobeNewswire
3/28
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
GlobeNewswire
3/22
HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highl...
GlobeNewswire
3/18
CIO Celebrates Innovations in Business Technology with 2024 CIO 100 & Hall of Fame Awards
GlobeNewswire
3/11
Hyku Biosciences, a Covalent Precision Medicine Company, Announces CEO Transition for its Next Phase...
GlobeNewswire
2/29
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CymaBay The...
GlobeNewswire
2/29
Abingworth Announces a Strategic Development Financing Agreement with Gilead Sciences; Establishes J...
GlobeNewswire
2/28
CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corpo...
